This observation might suggest that the increase of I-FABP in some COVID-19 patients might depend on the combination of pathological conditions that are in fine associated with marked alterations of the intestinal barrier, or perhaps related to bacterial diseases rather than viral diseases. This evidence concerns the gene FABP2 and COVID-19.